Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DERMASEAL is an investigational topical advanced wound-care dressing comprising a human plasma-derived fibrin film containing metallic silver microparticles. It is being developed as a combination biologic/device product for local management of chronic non-healing neuropathic diabetic foot ulcers and split-thickness skin-graft donor-site wounds. The fibrin film is intended to provide a wound-covering matrix, while the silver-containing component is intended to provide local antimicrobial activity. A Phase 1 diabetic-foot-ulcer study evaluated topical DERMASEAL plus standard of care, and a separate randomized study evaluated the dressing for skin-graft donor-site wounds. ([ctv.veeva.com](https://ctv.veeva.com/study/study-to-assess-the-safety-of-dermaseal-for-diabetic-foot-ulcers))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on DERMASEAL.